

## Smoking and Periodontal Treatment Outcome

Sotiria Tsantila<sup>1</sup>, Foteini Alexandridi<sup>2</sup> and Eudoxie Pepelassi<sup>3\*</sup>

<sup>1</sup>3 Dimitros Street, Mandra 19600 Attica, Greece

<sup>2</sup>33 Metaxa Street, Glyfada 16674 Athens, Greece

<sup>3</sup>Department of Periodontology, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece

\*Corresponding author: Pepelassi E, Associate Professor, Department of Periodontology, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece, Tel: 00302107461203; E-mail: epepela@dent.uoa.gr

Rec date: November 25, 2017; Acc date: December 17, 2017; Pub date: December 31, 2017

Copyright: © 2017 Tsantila S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

Smoking has harmful consequences for the general health and the oral cavity. The consequences of smoking on the general health have been sufficiently documented, though the list of diseases linked to smoking continues to become longer. The health consequences causally linked to smoking include cancers and chronic diseases. Periodontitis belongs to the diseases linked to smoking. For smokers, inhaling chemical compounds that originate from tobacco burning is a severe health hazard. Chronic nicotine consumption develops nicotine addiction. Moreover, secondhand and thirdhand smoking entails risks. The first aim of the present study was to review the diseases that are nowadays linked to smoking. The second aim of this study was to thoroughly review the literature related to the impact of smoking on the periodontal health, periodontal disease and periodontal treatment outcome. Smoking affects the inflammatory and immune response. Smoking is a risk factor for periodontitis. It negatively affects the presence and severity of periodontitis as well as the outcome of periodontal treatment. Smokers respond less favorably than non-smokers to non-surgical and surgical periodontal treatment. In terms of periodontal maintenance, disease recurrence and progression are common in smokers. The risk for progression of periodontitis is higher for smokers. It seems that smokers have reduced compliance with scheduled supportive periodontal treatment visits. The negative impact of smoking on the periodontium indicates that in terms of the periodontium smokers might benefit from smoking cessation.

**Keywords:** Periodontitis; Periodontal treatment; Periodontal treatment outcome; Periodontal disease progression; Smoking; Tobacco; Nicotine; Diseases linked to smoking

### Introduction

Cigarette smoking has been reduced since several decades ago. However, the epidemic of smoking continues. The quantity of nicotine consumption varies widely among people of different countries, country regions, races, ethnicities, educational levels and socioeconomic status. The initiation of smoking is usually early in life, which entails more prolonged exposure to nicotine and health risks.

Significant part of the risks of smoking originates from inhaling chemical compounds. These compounds are either contained in tobacco or are a result of tobacco burning. A great variety of chemicals are used to produce the cigarettes in the market. There are more than 7,000 chemicals and chemical compounds in tobacco smoke. Among them, there are numerous toxic or carcinogenic constituents. Smoke composition has been changed since several decades ago aiming at decreasing tar and nicotine smoke yields. Numerous physical processes and chemical reactions happen in the burning zone of a cigarette. There are liquid droplets in the cigarette smoke, which are suspended within a mixture of gases and semi-volatile compounds. During smoking, there are two kinds of smoke that differ in composition and properties. Specifically, the mainstream smoke is inhaled by the smoker and the side stream smoke is released into the environment from the lit end of the cigarette [1,2]. Nicotine, carbon monoxide, reactive oxidant substances (ROS), and acrolein are among the most significant cigarette smoke toxins [3,4].

Nicotine has psychoactive and addictive properties [3-5]. Addiction is most of the problem with nicotine [6]. Nicotine is the main addictive cigarette smoke constituent, though there are other chemicals that contribute directly or indirectly to the addictive effect of nicotine. Most smokers are addicted to nicotine. It has been suggested that the development of nicotine addiction is easier for children and adolescents than for adults [6]. For nicotine addicted smokers, nicotine absence often leads to nicotine craving and withdrawal symptoms [5]. With cigarette smoking, nicotine absorption from the lung and thereafter nicotine delivery to the brain are very rapid [5,7]. It is transported to brain within seconds. Brain delivery of nicotine results in the release of dopamine, which creates a heightened sense of alertness and contentment [5]. Nowadays, several cigarettes are more addictive than in the past. This is partly due to chemical compounds allowing nicotine to reach the brain more quickly [6].

There are several types of active nicotine consumption, such as cigarette smoking, smokeless tobacco chewing, water pipes and e-cigarettes [8]. Trends in tobacco use change and many people tend to use multiple tobacco products, particularly young people.

The consequences of smoking on the general health have been sufficiently documented, though the list of diseases linked to smoking continues to become longer. Therefore, the first aim of the present study was to review the diseases that are nowadays linked to smoking. The second and main aim of this study was to thoroughly review the literature related to the impact of smoking on the periodontal health, periodontal disease and periodontal treatment outcome.

## The Impact of Smoking on the General Health

Based on the 2014 United States Surgeon General's Report on the health consequences of smoking [6], cigarette smoking has been causally linked to diseases of nearly all organs of the body, to overall diminished health status and to harm to the fetus. The health consequences causally linked to smoking include cancers and chronic diseases. Additionally, cigarette smoking impairs immune function. Chronic nicotine use activates multiple biological pathways through which smoking increases risk for disease. Cancers in the oropharynx, larynx, esophagus, trachea, bronchus, lung, stomach, liver, pancreas, kidney, ureter, cervix, bladder and colorectal as well as acute myeloid leukemia have been causally linked to smoking. Stroke, blindness, cataracts, age-related macular degeneration, aortic aneurysm, early abdominal aortic atherosclerosis in young adults, coronary heart disease, pneumonia, chronic obstructive pulmonary disease, asthma, atherosclerotic peripheral vascular disease, tuberculosis, diabetes, rheumatoid arthritis and periodontitis are among the chronic diseases that have been causally linked to smoking. Furthermore, female reduced fertility and male erectile dysfunction have been causally linked to smoking. For women, the increased smoking prevalence seen as compared to the past led to significantly increased disease risks from smoking. Nowadays, women and men have equal risks from smoking to present lung cancer, chronic obstructive pulmonary disease, and cardiovascular diseases. Smoking during pregnancy negatively affects both the mother and the fetus. Orofacial cleft of the fetus has been causally linked to maternal smoking. There is sufficient evidence to infer that nicotine exposure during fetal development has lasting adverse consequences for brain development. There is sufficient evidence to infer that maternal smoking is related to preterm delivery and stillbirth. Concerning adolescents, the existing evidence suggests that nicotine exposure during adolescence may have lasting adverse consequences for brain development.

Based on the World Health Organization (WHO) estimate, one-third of the world's adult population is exposed involuntarily to cigarette smoke [9]. The main form of passive smoking is secondhand smoking. Secondhand smoking has been causally linked to cancer, respiratory, and cardiovascular diseases, and to adverse effects on the health of infants and children. Specifically, secondhand smoking has been causally linked to nasal irritation, stroke, lung cancer and coronary heart disease for the adults and to middle ear disease, respiratory symptoms, impaired lung function, lower respiratory illness, sudden infant death syndrome for the infants, children and adolescents. Thirdhand smoke, another form of passive smoking, is residual tobacco smoke contamination that remains after the cigarette is extinguished in the environment [10]. It consists of a mixture of volatile compounds and particulate matter that may be deposited or adsorbed on surfaces, including clothing, furniture, and upholstery [11]. With thirdhand smoke, toxic tobacco compounds, such as nitrosamines, remain in the environment [12]. Information on thirdhand smoke is very limited [12], especially on the possible health hazards for children [10]. It has been suggested that emphasizing that thirdhand smoke harms the health of children may be an important element in encouraging home smoking bans [10].

## Smoking and Periodontal Tissues

There is convincing cross-sectional evidence that smoking correlates inversely with deteriorating periodontal health and that this association may be dose-dependent [13-19]. Smoking is related to more severe periodontal condition [20].

The effect of smoking on the subgingival microflora was explored early in the literature [21-23] with varying results. Later, Apatzidou et al., found in periodontitis similar subgingival microflora for smokers and non-smokers [24]. The impact of smoking on the periodontium is not mainly mediated by changes in the microflora. Immunological changes in the host play a critical role in periodontal disease occurrence and progression [25]. Smoking affects the inflammatory and immune responses, including neutrophil function, antibody production, fibroblast activities and inflammatory mediator production, as well as the microvasculature. The impact of smoking on innate immunity ranges greatly from topical to systemic changes [3]. Smoking can directly affect the ability of the host to control the infection [25]. In periodontitis, smokers have a rather suppressed inflammatory response and an altered host antibody response to antigenic challenge than non-smokers [24].

Smoking increases total white blood cell count in the systemic circulation, affects neutrophils more than all white blood cells [26,27] and elicits the most destructive neutrophil actions [28]. It induces systemic neutrophilia [7], decreases neutrophil chemotaxis [29] and phagocytosis [30-33] with a dose-dependent effect [34] and increases the circulating neutrophil elastase and metalloproteinases (MMPs) [35,36], though it does not affect gingival crevicular neutrophil number [37].

Smoking activates inflammatory cells [38], increasing the systemic levels of various inflammatory markers, such as C-reactive protein, fibrinogen, interleukin-6 and haptoglobin [39]. It impairs humoral immune response [25]. The total leucocyte count was highest among heavy smokers (>10 cigarettes/day) and significantly higher compared with non-smokers irrespective of periodontitis presence or absence, and was reflected in increased neutrophil numbers but not in lymphocyte or monocyte numbers [38]. It decreases the levels of IgG, especially of IgG2 [40-42]. IgG2 levels are higher for non-smokers than smokers [43]. Smoking upregulates the expression of pro-inflammatory cytokines, such as interleukin-1 (IL-1) [44]. IL-1 genotype-positive smokers are more susceptible to severe chronic periodontitis [45]. The risk of severe clinical attachment level (CAL) loss was 4.5 times higher in IL-1 genotype-positive smokers compared to genotype-negative non-smokers. Among IL-1 genotype-negative individuals, smokers had 2.4 times higher chance of severe CAL loss than non-smokers. There is gene-environmental interaction between smoking and IL-1 genetic polymorphism [46].

The decrease in several pro-inflammatory cytokines, chemokines and T-cell regulators (interleukin-7 and interleukin-15) seen in smokers indicates the immunosuppressant effect of smoking contributing to an increased susceptibility to periodontitis [47]. Smoking suppresses certain Th1 responses, while it facilitates the generation of Th2 inflammation [48-52]. Tumor necrosis factor-alpha (TNF $\alpha$ ) significantly differed between smokers and non-smokers [53]. Reactive oxidant substances of cigarette smoke activate epithelial cell intracellular signaling cascades that lead to inflammatory gene activation, such as IL-8 and TNF $\alpha$  [54,55]. The secretion of these inflammatory mediators promotes chronic immune cell recruitment and inflammation. Smoking activates oral cells so that chronic inflammation is enhanced [56]. Moreover, it might dysregulate innate immune responses in the oral cavity by modifying local Toll-like receptor (TLR) expression, distribution and activation, which permits the development of chronic inflammation [57,58]. Furthermore, smoking impairs the vasculature of the periodontium and the gingival blood flow [7].

## The Impact of Smoking on the Periodontal Treatment Outcome

In smokers, clinical improvement with periodontal treatment has been documented following various therapeutic approaches. However, both extent and predictability of clinical improvement were significantly reduced with respect to non-smokers, even after corrections of oral hygiene levels [59-66]. Smokers respond less favorably than non-smokers to non-surgical [64,67] and surgical periodontal treatment [28,68-74].

In the short-term, both non-surgical and surgical approaches are less efficient in smokers than non-smokers [61,75]. Concerning the short-term response to non-surgical periodontal treatment, at 6 to 8 weeks smokers presented 0.7 mm less probing depth (PD) reduction and 0.4 mm less CAL gain than non-smokers [76] and at 6 months smokers had 0.9 mm less PD and 0.6 mm less CAL improvement at periodontitis sites (PD>5 mm, CAL>3 mm) than non-smokers [77]. Palmer and Soory stated that in non-surgical treatment, smoking is associated with poorer PD and CAL improvement (approximately 0.5 mm less) and that in most studies smokers have lower bleeding level at baseline, and following treatment there is similar bleeding reduction for smokers and non-smokers [78]. In a systematic review on smoking effect on non-surgical treatment, Labriola et al. found that for all sites the PD reduction was 0.13 mm greater in non-smokers than smokers (6 studies). CAL gain and bleeding reduction did not differ between smokers and non-smokers [69]. A longitudinal study over 6 years demonstrated a continuously inferior treatment outcome in smokers. Specifically, less PD and CAL improvement and greater horizontal CAL loss were found in smokers than non-smokers [62]. Mdala et al. in a two-year study showed that past and present smoking significantly increased PD and that current smokers were at higher risk of CAL loss [79].

An increased need for surgical treatment could be expected for smokers [80], since smoking has a negative impact on PD reduction after non-surgical treatment [62,75]. Kotsakis et al. [81] in a systematic review and meta-analysis on the impact of smoking on the clinical outcomes following periodontal flap surgical procedures found improved treatment effect among non-smokers compared with smokers. PD reduction in smokers and non-smokers ranged from 0.76 to 2.05 mm and 1.27 to 2.40 mm, respectively. CAL gain in smokers and non-smokers ranged from 0.29 to 1.6 mm and 0.09 to 1.2 mm, respectively. Meta-analysis demonstrated for non-smokers an increased PD and CAL improvement of 0.39 and 0.35 mm, respectively. They concluded that smokers could be candidates for periodontal flap surgical procedures. Though, the magnitude of the therapeutic effect is compromised in smokers compared with non-smokers. Therefore, smokers should be encouraged to abstain from smoking and should be thoroughly informed preoperatively of substantial reduction in clinical outcomes.

Concerning endosseous defects, a Consensus Report from the American Academy of Periodontology (AAP) Regeneration Workshop in 2015 concluded that the outcomes of periodontal regeneration are negatively affected by smoking [82]. Patel et al. in their systematic review and meta-analysis studied the effect of smoking on periodontal bone regeneration in endosseous defects [83]. Six of the 10 studies concluded that smoking significantly negatively influenced post-treatment bone gain or fill [84-87]. Ehmke et al. reported mean bone gain of 0.2 mm in smokers compared to 2.2 mm in non-smokers after the use of bio absorbable membrane [87]. Heden reported bone gain of

2.6 mm in smokers compared to 3.3 mm in non-smokers after the use of Emdogain (EMD) [85]. Two of the 10 studies reported no significant difference in bone gain between smokers and non-smokers after EMD [88] or beta-tricalcium phosphate (b-TCP) and recombinant human platelet-derived growth factor [89]. The meta-analysis by Patel et al. showed a standardized mean difference of -2.05 (95% CI: -2.64 to -1.47) in probing bone level change for smokers and non-smokers after regenerative treatment [83]. When the long-term stability of CAL following guided tissue regeneration (GTR) and conventional therapy was evaluated, it was found that most patients with further CAL loss were non-compliant and smokers, while most patients with stable periodontal conditions were compliant and non-smokers [90].

Smoking adversely affects GTR outcomes for root coverage purposes in terms of recession reduction, root coverage, CAL gain and probing-bone improvement [91]. Concerning smoking effect on the outcomes achieved by root-coverage procedures, a meta-analysis by Chambrone et al. showed that the use of subepithelial connective-tissue (CT) graft was less effective in smokers than non-smokers in reducing root exposure and improving CAL. There was greater chance of achieving complete root coverage in non-smokers (27 to 80%) than smokers (0 to 25%). After CT graft, smokers had fewer sites exhibiting complete root coverage than did non-smokers [72]. It has been reported that the percentage (%) of mean root coverage at 6 months after CT graft varied according to the level of cotinine in saliva (84.2% for 10- to 40-ng/mL cotinine levels and 76. % for cotinine levels >40 ng/mL) and that higher cotinine levels were negatively associated with root coverage [92]. Recurrence of gingival recession after root coverage procedures was more evident for smokers than non-smokers [93,94]. Concerning the smoking effect on the outcomes achieved by coronally advanced flap for root-coverage, Chambrone et al. [72] in their meta-analysis found similar results between smokers and non-smokers. Though, there were only two studies available for analysis [94,95] that differed in design. It should be emphasized that in one [94] of them the long-term (two-year) healing response was affected by smoking.

## Smoking and Periodontal Maintenance

Periodontal treatment leads to clinical improvement both in smokers and non-smokers, though disease recurrence and progression is common in smokers. Cortellini et al. in 1996 showed that in the long-term most patients who lost CAL after active treatment were non-compliant and smokers [90]. Kaldhal et al. in 1996 reported deterioration of the periodontal condition during periodontal maintenance for heavy smokers [96]. Tonetti et al. in 1998 found that during periodontal maintenance, the prevalence of bleeding residual pockets was significantly increased for smokers as compared with never smokers and former smokers [97]. Ah et al. showed that self-reported smokers exhibited less CAL and PD improvement over each of 6 years of maintenance compared with self-reported non-smokers, though these differences were small (<0.5 mm) and their clinical importance was questioned [62]. Furthermore, the same research group found that, over 7 years of regular maintenance, self-reported light and heavy smokers exhibited less CAL and PD improvement compared with non-smokers or former smokers. The clinical importance of these differences was limited, since they were small for the entire 7-year maintenance period (<1 mm) [98]. In a relatively recent study smoking had a negative periodontal effect at 12 months of maintenance. It affected the presence of sites with bleeding residual (PD ≥ 5 mm) pockets. In smokers, bleeding on probing (BOP) at 3



months after active treatment was a strong site-specific predictor for residual pockets with BOP at 12 months of maintenance [99].

Data reveals that following a strict periodontal maintenance care program is imperative for smokers. Specifically, Papantonopoulos, in well-maintained advanced periodontitis patients showed absence of significant difference in PD and radiographically imaged bone loss over a 5 to 8-year period between smokers and non-smokers [68]. Fisher et al. in a 3-year study of well-maintained chronic periodontitis patients failed to demonstrate any statistically significant differences in disease progression (CAL and PD), inflammatory indices (PI and BOP) and tooth loss between current smokers and validated current non-smokers. Hence, in this small study of highly motivated individuals receiving optimal care in a hospital clinic, regular maintenance treatment seemed equally successful in preventing progressive periodontal destruction in current smokers and current non-smokers with chronic periodontitis [100].

In McGuire and Nunn's study heavy smoking was significantly related to tooth loss in patients under periodontal maintenance for 14 years. Most of these patients were compliant with maintenance visits, though presenting fair oral hygiene [101]. In terms of tooth loss due to periodontitis during maintenance, it has been found that smokers ( $\geq 10$  cigarettes per day) might have almost five times greater risk of tooth loss even while complying with strict periodontal maintenance [102].

In terms of aggressive periodontitis, smoking was the main significant risk factor for disease recurrence during maintenance (defined as the occurrence of PD  $\geq 5$  mm at  $\geq 30\%$  of the teeth) [103]. Furthermore, nearly significant correlations were reported between smoking and tooth loss in aggressive periodontitis [104].

The influence of smoking on compliance with scheduled supportive periodontal treatment (SPT) visits has not been thoroughly explored, since there is only limited information on this [80,105]. Ramseier et al. found that smokers tend to return less likely for scheduled SPT visits than non-smokers or former smokers. Even after adjusting for possible confounders, such as gender, age, disease severity or active treatment duration, the effect of smoking remained significant [106]. Their finding on reduced compliance of smokers with scheduled SPT visits agrees with previous findings on higher frequency of smokers in the non-compliant group [80,105].

Smokers had greater risk for further CAL loss (odds ratios of 2.3 to 4.8 for light to heavy smokers, respectively) [107] and for further alveolar crest height loss (3.2 to 7.3 for light to heavy smokers, respectively) [108]. Smoking is a risk factor for further progression of periodontitis during maintenance. The strong relation between smoking and periodontitis progression should be taken under consideration for the risk assessment of disease progression at the patient level in periodontal maintenance. During maintenance, clinicians should recall smokers more frequently than non-smokers [20] and they should maintain their efforts to verify that smokers keep their scheduled SPT appointments [106].

The harmful effect of smoking on the periodontium demonstrates that non-smokers should not start the smoking habit and that smokers should quit smoking. Dentists may play an important role in the smoking cessation effort by advising and motivating all patients who smoke to quit smoking and supporting the attempting to quit patients in achieving their goal [109].

## Conclusion

Smoking is harmful for the general health and the oral cavity. The list of cancers and chronic diseases causally linked to smoking is long and keeps increasing. In terms of the periodontium, smoking negatively affects the presence and severity of periodontal disease and the outcome of periodontal treatment. Both for smokers and non-smokers, there is clinical improvement with periodontal treatment. Though, smokers respond less favorably than non-smokers to non-surgical periodontal treatment, to flap surgical procedures, to periodontal regeneration in endosseous defects and to root coverage procedures. Periodontal disease recurrence and progression is common in smokers. Smokers present higher risk of periodontal disease progression. Therefore, they should be recalled more frequently, and the dentist should verify that they keep their scheduled periodontal maintenance appointments. The negative impact of smoking on the periodontium indicates that in terms of the periodontium smokers might benefit from smoking cessation.

## References

- Thielen A, Klus H, Muller L (2008) Tobacco smoke: unraveling a controversial subject. *Exp Toxicol Pathol* 60: 141-156.
- Rodgman A, Perfetti TA (2013) The chemical components of tobacco and tobacco smoke. 2nd edn, Boca Raton, Florida: CRC Press.
- Lee J, Tanela V, Vassallo R (2012) Cigarette smoking and inflammation: Cellular and Molecular Mechanisms. *J Dent Res* 91: 142-149.
- Benowitz NL (1996) Pharmacology of nicotine: addiction and therapeutics. *Annu Rev Pharmacol Toxicol* 36: 597-613.
- Royal Australian College of General Practitioners (2011) Supporting smoking cessation: A guide for health professionals, Melbourne.
- The Health Consequences of Smoking—50 Years of Progress (2014) a report of the surgeon general. In: US Department of Health and Human Services.
- Palmer RM, Wilson RF, Hasan AS, Scott DA (2005) Mechanisms of action of environmental factors – tobacco smoking. *J Clin Periodontol* 32: 180-195.
- Eriksen M, Mackay J, Schluger N, Islami F, Drope J (2015) The tobacco atlas. 5th edn. American Cancer Society.
- <http://www.who.int/indoorair/publications/9789289002134/en/>.
- <http://pediatrics.aappublications.org/content/123/1/e74.short>.
- Matt GE, Quintana PJ, Zakarian JM, Fortmann AL, Chatfield DA, et al. (2011) When smokers move out and non-smokers move in: residential thirdhand smoke pollution and exposure. *Tob Control* 20: 1.
- Figueiró LR, Ziulkoski AL, Dantas DC (2016) Thirdhand smoke: when the danger is more than you can see or smell. *Cadernos de saude publica* 2016: 32.
- Haber J, Wattles J, Crowley M, Mandell R, Josphura K, et al. (1993) Evidence for cigarette smoking as a major risk factor for periodontitis. *J Periodontol* 64: 16-23.
- Gonzalez YM, De Nardin A, Grossi SG, Machtei EE, Genco RJ, et al. (1996) Serum cotinine levels, smoking, and periodontal attachment loss. *J Dental Res* 75: 796-802.
- Gelskey SC (1999) Cigarette smoking and periodontitis: Methodology to assess the strength of evidence in support of a causal association. *Community Dent Oral Epidemiol* 27: 16-24.
- Haffajee AD, Socransky SS (2001) Relationship of cigarette smoking to attachment level profiles. *J Clin Periodontol* 28: 283-295.
- Jansson L, Lavstedt S (2002) Influence of smoking on marginal bone loss and tooth loss – A prospective study over 20 years. *J Clin Periodontol* 29: 750-756.

18. Razali M, Palmer RM, Coward P, Wilson RF (2005) A retrospective study of periodontal disease severity in smokers and non-smokers. *Br Dent J* 198: 495-498.
19. Baharin B, Palmer RM, Coward P, Wilson RF (2006) Investigation of periodontal destruction patterns in smokers and non-smokers. *J Clin Periodontol* 33: 485-490.
20. Sham A, Cheung LK, Jin LJ, Corbett EF (2003) The effects of tobacco use on oral health- Review Article. *Hong Kong Med J* 9: 271-277.
21. Preber H, Bergstrom J, Linder LE (1992) Occurrence of periopathogens in smoker and non-smoker patients. *J Clin Periodontol* 19: 667-671.
22. Zambon JJ, Grossi SG, Machtei EE, Ho AW, Dunford R, et al. (1996) Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. *J Periodontol* 67: 1050-1054.
23. Umeda M, Chen C, Bakker I, Contreras A, Morrison JL, et al. (1998) Risk indicators for harboring periodontal pathogens. *J Periodontol* 69: 1111-1118.
24. Apatzidou DA, Riggio MP, Kinane DF (2005) Impact of smoking on the clinical, microbiological and immunological parameters of adult patients with periodontitis. *J Clin Periodontol* 32: 973-983.
25. Johannsen A, Susin C, Gustafsson A (2014) Smoking and inflammation: evidence for a synergistic role in chronic disease. *Periodontol* 2000 64: 111-126.
26. Smith MR, Kinmonth AL, Luben RN, Bingham S, Day NE, et al. (2003) Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. *Atherosclerosis* 169: 331-337.
27. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, et al. (2005) Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. *Eur Heart J* 26: 1765-1773.
28. Johnson G, Guthmiller J (2007) The impact of cigarette smoking on periodontal disease and treatment. *Periodontol* 2000 44: 178-194.
29. Noble RC, Penny BB (1975) Comparison of leukocyte count and function in smoking and nonsmoking young men. *Infect Immun* 12: 550-555.
30. Kenney EB, Kraal JH, Saxe SR, Jones J (1977) The effect of cigarette smoke on human oral polymorphonuclear leukocytes. *J Periodontal Res* 12: 227-234.
31. Corberand J, Laharrague P, Nguyen F (1980) In vitro effect of tobacco smoke components on the functions of normal human polymorphonuclear leukocytes. *Infect Immun* 30: 649-655.
32. Guntch A, Erler M, Preshaw PM, Sigusch BW, Klinger G, et al. (2006) Effect of smoking on crevicular polymorphonuclear neutrophil function in periodontally healthy subjects. *J Periodont Res* 41: 184-188.
33. Zappacosta B, Martorana GE, Papini S, Gervasoni J, Iavarone F, et al. (2011) Morphofunctional modifications of human neutrophils induced by aqueous cigarette smoke extract: comparison with chemiluminescence activity. *Luminescence* 26: 331-335.
34. Seow WK, Thong YH, Nelson RD, MacFarlane GD, Herzberg MC (1994) Nicotine-induced release of elastase and eicosanoids by human neutrophils. *Inflammation* 18: 119-127.
35. Nakamura T, Ebihara I, Shimada N, Koide H (1998) Effect of cigarette smoking on plasma metalloproteinase-9 concentration. *Clinica Chimica Acta* 276: 173-177.
36. Van Eeden SF, Hogg JC (2000) The response of human bone marrow to chronic cigarette smoking. *European Respiratory Journal* 15: 915-921.
37. Pauletto NC, Liede K, Nieminen A, Larjava H, Uitto VJ (2000) Effect of cigarette smoking on oral elastase activity in adult periodontitis patients. *J Periodontol* 71: 58-62.
38. Loos BG, Roos MT, Schellekens PT, van der Velden U, Miedema F (2004) Lymphocyte numbers and function in relation to periodontitis and smoking. *J Periodontol* 75: 557-564.
39. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. *Chest* 131: 1557-1566.
40. Gerrard JW, Heiner DC, Ko CG, Mink J, Meyers A, et al. (1980) Immunoglobulin levels in smokers and non-smokers. *Ann Allergy* 44: 261-262.
41. Moszczynski P, Zabinski Z, Moszczynski P Jr, Rutowski J, Slowinski S, et al. (2001) Immunological findings in cigarette smokers. *Toxicol Lett* 118: 121-127.
42. Qvarfordt I, Riise GC, Andersson BA, Larsson S (2001) IgG subclasses in smokers with chronic bronchitis and recurrent exacerbations. *Thorax* 56: 445-449.
43. Graswinkel JE, van der Velden U, van Winkelhoff AJ, Hoek FJ, Loos BG (2004) Plasma antibody levels in periodontitis patients and controls. *J Clin Periodontol* 31: 562-568.
44. Travis J, Pike R, Imamura T, Potempa J (1994) The role of proteolytic enzymes in the development of pulmonary emphysema and periodontal disease. *Am J Respir Crit Care Med* 150: 143-146.
45. Meisel P, Siegemund A, Dombrowa S, Sawaf H, Fanghaenel J, et al. (2002) Smoking and polymorphisms of the interleukin-1 gene cluster (IL-1alpha, IL-1beta, and IL-1RN) in patients with periodontal disease. *J Periodontol* 73: 27-32.
46. Meisel P, Schwahn C, Gesch D, Bernhardt O, John U, et al. (2004) Dose-effect relation of smoking and the interleukin-1 gene polymorphism in periodontal disease. *J Periodontol* 75: 236-242.
47. Tymkiw KD, Thunell DH, Johnson GK, Joly S, Burnell KK, et al. (2011) Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. *J Clin Periodontol* 38: 219-228.
48. Cozen W, Diaz-Sanchez D, James Gauderman W, Zadnick J, Cockburn MG, et al. (2004) Th1 and Th2 cytokines and IgE levels in identical twins with varying levels of cigarette consumption. *J Clin Immunol* 24: 617-622.
49. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L (2005) Cigarette smoke extract suppresses human dendritic cell function leading to preferential induction of Th-2 priming. *J Immunol* 175: 2684-2691.
50. Nakamura Y, Miyata M, Ohba T, Ando T, Hatsushika K, et al. (2008) Cigarette smoke extract induces thymic stromal lymphopoietin expression, leading to T(H)2-type immune responses and airway inflammation. *J Allergy Clin Immunol* 122: 1208-1214.
51. de Heens GL, van der Velden U, Loos BG (2009) Cigarette smoking enhances T cell activation and a Th2 immune response; an aspect of the pathophysiology in periodontal disease. *Cytokine* 47: 157-161.
52. Robays LJ, Lanckacker EA, Moerlose KB, Maes T, Bracke KR, et al. (2009) Concomitant inhalation of cigarette smoke and aerosolized protein activates airway dendritic cells and induces allergic airway inflammation in a TLR-independent way. *J Immunol* 183: 2758-2766.
53. Bostrom L, Linder LE, Bergstrom J (1998) Influence of smoking on the outcome of periodontal surgery. A 5-year follow-up. *J Clin Periodontol* 25: 194-201.
54. Churg A, Dai J, Tai H, Xie C, Wright JL (2002) Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. *Am J Respir Crit Care Med* 166: 849-854.
55. Chung KF (2005) Inflammatory mediators in chronic obstructive pulmonary disease. *Curr Drug Targets Inflamm Allergy* 4: 619-625.
56. Mahanonda R, Sa-Ard-Iam N, Eksomtramate M, Rerkyen P, Phairat B, et al. (2009) Cigarette smoke extract modulates human beta-defensin-2 and interleukin-8 expression in human gingival epithelial cells. *J Periodontal Res* 44: 557-564.
57. Beklen A, Hukkanen M, Richardson R, Kontinen YT (2008) Immunohistochemical localization of Toll-like receptors 1-10 in periodontitis. *Oral Microbiol Immunol* 23: 425-431.
58. Pace E, Ferraro M, Siena L, Melis M, Montalbano AM, et al. (2008) Cigarette smoke increases Toll-like receptor 4 and modifies lipopolysaccharide-mediated responses in airway epithelial cells. *Immunology* 124: 401-411.
59. Preber H, Bergstrom J (1986) The effect of non-surgical treatment on periodontal pockets in smokers and non-smokers. *J Clin Periodontol* 13: 319-323.
60. Miller PD (1987) Root coverage with the free gingival graft. Factors associated with incomplete root coverage. *J Periodontol* 58: 674-681.
61. Preber H, Bergstrom J (1990) Effects of cigarette smoking on periodontal healing following surgical therapy. *J Clin Periodontol* 17: 324-328.

62. Ah M, Johnson G, Kaldahl W, Patil K, Kalkwarf K (1994) The effect of smoking on the response to periodontal therapy. *J Clin Periodontol* 21: 91-97.
63. Tonetti M, Pini-Prato G, Tortellini P (1995) Effect of cigarette smoking on periodontal healing following GTR in infra bony defects. A preliminary retrospective study. *J Clin Periodontol* 22: 229-234.
64. Grossi S, Skrepicinski F, DeCaro T, Zambon J, Cummins D, et al. (1996) Response to periodontal therapy in diabetics and smokers. *J Periodontol* 67: 1094-1102.
65. Rosen PS, Marks MH, Reynolds MA (1996) Influence of smoking on long-term clinical results of intrabony defects treated with regenerative therapy. *J Periodontol* 67: 1159-1163.
66. Kinane D, Radvar M (1997) The effect of smoking on mechanical and antimicrobial therapy. *J Periodontol* 68: 467-472.
67. Preber H, Linder L, Bergstrom J (1995) Periodontal healing and periopathogenic microflora in smokers and non-smokers. *J Clin Periodontol* 22: 946-952.
68. Papantonopoulos G (2004) Effect of Periodontal Therapy in Smokers and non-Smokers with Advanced Periodontal Disease : Results After Maintenance Therapy for a Minimum of 5 years. *J Periodontol* 75: 839-843.
69. Garcia RI (2005) Smokers have less reductions in probing depth than non-smokers following nonsurgical periodontal therapy. *Evidence-based Dentistry* 6: 37-38.
70. Bergstrom J (2006) Periodontitis and smoking: an evidence-based appraisal. *J Evid Base Dent Pract* 6: 33-41.
71. Heasman L, Stacey F, Preshaw PM, McCracken GI, Hepburn S, et al. (2006) The effect of smoking on periodontal treatment response: a review of clinical evidence. *J Clin Periodontol* 33: 241-253.
72. Chambrone L, Chambrone D, Pustigliani FE, Chambrone LA, Lima LA (2009) The influence of tobacco smoking on the outcomes achieved by root-coverage procedures. A systematic review. *J Am Dent Assoc* 140: 294-306.
73. Wan CP, Leung WK, Wong MC, Wong RM, Wan P, et al. (2009) Effects of smoking on healing response to non-surgical periodontal therapy: a multilevel modelling analysis. *J Clin Periodontol* 36: 229-239.
74. Rosa EF, Corraini P, de Carvalho VF, Inoue G, Gomes EF, et al. (2011) A prospective 12-month study of the effect of smoking cessation on periodontal clinical parameters. *J Clin Periodontol* 38: 562-571.
75. Preber H, Bergstrom J (1985) Occurrence of gingival bleeding in smoker and non- smoker patients. *Acta Odontol Scand* 43: 315-320.
76. Darby IB, Hodge PJ, Riggio MP, Kinane DF (2005) Clinical and microbiological effect of scaling and root planing in smoker and non-smoker chronic and aggressive periodontitis patients. *J Clin Periodontol* 32: 200-206.
77. Jin L, Wong KY, Leung WK, Corbet EF (2000) Comparison of treatment response patterns following scaling and root planing in smokers and non-smokers with untreated adult periodontitis. *J Clin Dent* 11: 35-41.
78. Lindhe J, Lang N, Karring T (2008) *Clinical Periodontology and Implant Dentistry*. 5th edn. Copenhagen: Blackwell Munksgaard
79. Mdala I, Haffajee AD, Socransky SS, Freiesleben de Blasio B, Thoresen M, et al. (2012) Multilevel analysis of clinical parameters in chronic periodontitis after root planing/scaling, surgery, and systemic and local antibiotics: 2 year- results. *J Oral Microbiol* 4: 17535.
80. Jansson L, Hagstrom K (2002) Relationship Between Compliance and Periodontal Treatment Outcome in Smokers. *J Periodontol* 73: 602-607.
81. Kotsakis G, Javed F, Hinrichs J, Karoussis I, Romanos G (2015) Impact of Cigarette Smoking on Clinical Outcomes of Periodontal Flap Surgical Procedures: A Systematic Review and Meta-Analysis. *J Periodontol* 86: 254-263.
82. Reynolds MA, Kao RT, Camargo PM, Caton JG, Clem DS, et al. (2015) Periodontal Regeneration – Intrabony Defects: A Consensus Report From the AAP Regeneration Workshop. *J Periodontol* 86: S105-S107.
83. Patel RA, Wilson RF, Palmer RM (2012) The Effect of Smoking on Periodontal Bone Regeneration: A Systematic Review and Meta-Analysis. *J Periodontol* 83: 143-155.
84. Luepke PG, Mellonig JT, Brunsvold MA (1997) A clinical evaluation of a bioresorbable barrier with and without decalcified freeze-dried bone allograft in the treatment of molar furcations. *J Clin Periodontol* 24: 440-446.
85. Heden G (2000) A case report study of 72 consecutive Emdogain-treated intrabony periodontal defects: Clinical and radiographic findings after 1 year. *Int J Periodontics Restorative Dent* 20: 127-139.
86. Loos BG, Louwse PH, Van Winkelhoff AJ, Burger W, Giliyamse M, et al. (2002) Use of barrier membranes and systemic antibiotics in the treatment of intraosseous defects. *J Clin Periodontol* 29: 910-921.
87. Ehmke B, Rudiger SG, Hommens A, Karch H, Flemmig TF (2003) Guided tissue regeneration using a polylactic acid barrier. Part II: Predictors influencing treatment outcome. *J Clin Periodontol* 30: 368-374.
88. Trombelli L, Bottega S, Zucchelli G (2002) Supracrestal soft tissue preservation with enamel matrix proteins in treatment of deep intrabony defects. *J Clin Periodontol* 29: 433-439.
89. Nevins M, Giannobile WV, McGuire MK, Kao RT, Mellonig JT, et al. (2005) Platelet- derived growth factor stimulates bone fill and rate of attachment level gain: Results of a large multicenter randomized controlled trial. *J Periodontol* 76: 2205-2215.
90. Cortellini P, Paolo G, Prato P, Tonneti M (1996) Long-term stability of clinical attachment following guided tissue regeneration and conventional therapy. *J Clin Periodontol* 23: 106-111.
91. Trombelli L, Scabbia A (1997) Healing response of gingival recession defects following guided tissue regeneration procedures in smokers and non- smokers. *J Clin Periodontol* 24: 529-533.
92. Erley KJ, Swiec GD, Herold R, Bisch FC, Peacock ME (2006) Gingival recession treatment with connective tissue grafts in smokers and non-smokers. *J Periodontol* 77: 1148-1155.
93. Silva CO, Sallum AW, de Lima AF, Tatakis DN (2006) Coronally positioned flap for root coverage: poorer outcomes in smokers. *J Periodontol* 77: 81-87.
94. Silva CO, de Lima AF, Sallum AW, Tatakis DN (2007) Coronally positioned flap for root coverage in smokers and non-smokers: stability of outcomes between 6 months and 2 years. *J Periodontol* 78: 1702-1707.
95. Pini Prato GP, Baldi C, Nieri M, Franseshci D, Cortellini P, et al. (2005) Coronally advanced flap: the post-surgical position of the gingival margin is an important factor for achieving complete root coverage. *J Periodontol* 76: 713-722.
96. Kaldhal W, Kalkwarf K, Patjl K, Molvar M, Dyer J (1996) Long term evaluation of periodontal therapy (I). Response to 4 treatment modalities. *J Periodontol* 67: 93-102.
97. Tonetti MS, Muller-Campanile V, Lang NP (1998) Changes in the prevalence of residual pockets and tooth loss in treated periodontal patients during a supportive maintenance care program. *J Clin Periodontol* 25: 1008-1016.
98. Kaldhal WB, Johnson GK, Patil KD, Kalkwarf KL (1996) Levels of cigarette consumption and response to periodontal therapy. *J Periodontol* 67: 675-681.
99. Bunæs DF, Lie SA, Astrøm AN, Mustafa K, Leknes KN (2106) Site-specific treatment outcome in smokers following 12 months of supportive periodontal therapy. *J Clin Periodontol* 43: 1086-1093.
100. Fisher S, Kells L, Picard JP, Gelskey SC, Singer DL, et al. (2008) Progression of Periodontal Disease in a Maintenance Population of Smokers and Non-Smokers: A 3-year longitudinal study. *J Periodontol* 79: 461-468.
101. McGuire KM, Nunn ME (1999) Prognosis versus actual outcome. IV. The effectiveness of clinical parameters and IL-1 genotype in accurately predicting prognosis and tooth survival. *J Periodontol* 70: 49-56.
102. Chambrone L, Preshaw PM, Rosa EF, Heasman PA, Romito GA, et al. (2013) Effects of smoking cessation on the outcomes of non-surgical

- 
- periodontal therapy: a systematic review and individual patient data meta-analysis. *J Clin Periodontol* 40: 607-615.
103. Baumer A, Pretzl B, Cosgarea R, Kim TS, Reitmeir P, et al. (2011) Tooth loss in aggressive periodontitis after active periodontal therapy: patient-related and tooth-related prognostic factors. *J Clin Periodontol* 38: 644-651.
104. Teughels W, Dhondt R, Dekeyser C, Quirynen M (2014) Treatment of Aggressive Periodontitis. *Periodontology* 2000 65: 107-133.
105. Mendoza AR, Newcomb GM, Nixon KC (1991) Compliance with supportive periodontal therapy. *J Periodontol* 62: 731-736.
106. Ramseier CA, Kobrehel S, Staub P, Sculean A, Lang NP, et al. (2014) Compliance of cigarette smokers with scheduled visits for supportive periodontal therapy. *J Clin Periodontol* 41: 473-480.
107. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, et al. (1994) Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. *J Periodontol* 65: 260-267.
108. Grossi SG, Genco RI, Machtei EE, Ho AW, Koch G, et al. (1995) Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. *J Periodontol* 66: 23-29.
109. Alexandridi F, Tsantila S, Pepelassi E (2017) Smoking cessation and response to periodontal treatment.